The FDA accepted a protocol amendment for the NANORAY-312 study, which is sponsored by Johnson & Johnson.
1 report, 1 independent
Updated Jun 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA accepted a protocol amendment for the NANORAY-312 study, which is sponsored by Johnson & Johnson.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Johnson & Johnson
Czech company
Nothing else this week.
Related events
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
- The FDA has issued a Major Amendment regarding AxoGen's submission on August 25, 2025.
- Technology received 12 FDA regulatory authorizations, with Senator Mark Warner attending the event.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.